Rigel's positive PhIII for bleeding disorder triggers a roller coaster ride for shares
A failure-prone Rigel Pharmaceuticals claimed a much-needed win in a Phase III study of its lead drug. And the news spurred a temporary spike …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
